TapImmune's technology has broad applications in developing therapeutic and preventative vaccines.

Our strategy is to build a patented proprietary product pipeline and capitalize on the breadth of the TAP technology through collaborative partnerships and license agreements.

To achieve success, TapImmune's strategy for growth is to:

• Conduct preclinical vaccine programs and move successes through to human trials
• Discover, acquire and develop technologies that modulate antigen presentation
• Commercialize proprietary products through corporate alliances
• Develop business partnerships that enhance the efficacy of other immunotherapeutic and vaccine products